Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

• Status: Completed
• Trial end date: 2017-09-30
• Target enrollment: 0
• Participant gender: Male

Summary

The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and subsequent treatments.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Radium Ra 223 dichloride; Succinylcholine

Criteria

Inclusion Criteria:

• First diagnosis for bone metastases for members diagnosed with prostate cancer found in the claims data during the identification period

• Members age ≥ 55 to 89 years at index

• Medicare members with medical and pharmacy coverage; and

• Continuously enrolled during the pre- and post-index periods.

Exclusion Criteria:

• Member with diagnosis of any other cancer (excluding melanoma (ICD-9 172.x) and other metastases (ICD-9 198.x)) before the index date; and

• Members age ≥ 89 years of age at index date